Pelthos Therapeutics reports Q2 2026 revenue growth on Zelsuvmi demand
Pelthos Therapeutics said second-quarter 2026 net product revenue rose to $15.4 million from $10.7 million in Q1, as Zelsuvmi prescription units increased 48% to 11,925.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.